Osimertinib is one of the standard second-line therapy choices for patients with progressive T790M-positive NSCLC following relapse beyond first-line therapy with a first- or second-generation EGFR-TKI [24]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.